Alström Syndrome (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Alström Syndrome (AS) is an ultra-rare multisystem genetic disorder caused by pathogenic variants of the ALMS1 gene. The disease is relentlessly progressive in nature which can result in premature death. Misdiagnosis is common. Because so many features of Alström Syndrome develop as children get older, more than seventy percent of the known Alström Syndrome patients have received previous misdiagnoses, and almost half of these have received multiple misdiagnoses. It progresses to severe visual impairment by the end of the second decade in 75%. Obesity develops in early childhood. Progressive bilateral sensorineural hearing loss is more variable, often presenting with high-frequency loss in the first decade but not detectable until much later in the minority. More than 60% of individuals with AS develop cardiomyopathy. This can present as potentially reversible dilated cardiomyopathy in infancy or presenting de novo or recurrence in adolescence with progression to a restrictive pattern. Insulin resistance is present from infancy- and progression to glucose intolerance is partly related to the degree of obesity. Molecular genetic testing of ALMS1, the only gene in which mutations are known to cause Alström syndrome, is estimated to detect mutations in 70%-80% of individuals of northern European descent and approximately 40% worldwide.

·       Prevalence range from 1:10,000 in communities where first cousin marriages are customary to fewer than 1:1,000,000 in populations with low levels of consanguineous marriages.

 

Thelansis’s “Alström Syndrome (AS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alström Syndrome (AS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Alström Syndrome (AS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Alström Syndrome (AS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Alström Syndrome (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Alström Syndrome (AS), Alström Syndrome (AS) market outlook, Alström Syndrome (AS) competitive landscape, Alström Syndrome (AS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)